3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
19
Lung Neoplasms
10
Stomach Neoplasms
8
Neoplasm Metastasis
6
Colorectal Neoplasms
6
Breast Neoplasms
6
Nasopharyngeal Carcinoma
5
Leukemia, Myeloid, Acute
5
Esophageal Neoplasms
5
Small Cell Lung Carcinoma
4
Pancreatic Neoplasms
4
Neoplasms
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Ovarian Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Endometrial Neoplasms
3
Adenocarcinoma Of Esophagus
3
Urinary Bladder Neoplasms
2
Rectal Neoplasms
2
Mouth Neoplasms
2
Lymphoma
2
Head and Neck Neoplasms
2
Glioma
2
Glioblastoma
2
Carcinoma, Squamous Cell
2
Anatomic Stage II Breast Cancer AJCC v8
2
Advanced Solid Tumors
2
Unresectable Locally Recurrent Rectal Cancer
1
Thymoma
1
Interventions
Cyclophosphamide
23
fludarabine
14
Rituximab
14
Specimen Handling
8
Magnetic Resonance Spectroscopy
7
Doxorubicin
7
pirtobrutinib
6
Vincristine
6
Prednisone
6
zanubrutinib
4
polatuzumab vedotin
4
obinutuzumab
4
Nivolumab
4
Etoposide
4
Dexamethasone
4
Biopsy
4
tazemetostat
3
tafasitamab
3
pembrolizumab
3
ibrutinib
3
glofitamab
3
fludarabine phosphate
3
acalabrutinib
3
Immunotherapy, Adoptive
3
Bendamustine Hydrochloride
3
venetoclax
2
pomalidomide
2
etoposide phosphate
2
cemiplimab
2
Prednisolone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell
×
Drug Therapy
×
90 days
×
Clear all
NCT03570892
2026-05-14
BELINDA
Novartis
Phase 3
Completed
330 enrolled
10 charts